Investigation of imaging the somatostatin receptor by opening the blood-brain barrier with melittin – A feasibility study using positron emission tomography and [64Cu]Cu-DOTATATE

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Investigation of imaging the somatostatin receptor by opening the blood-brain barrier with melittin – A feasibility study using positron emission tomography and [64Cu]Cu-DOTATATE. / Andersen, Ida Vang; Bidesi, Natasha Shalina Rajani; Shalgunov, Vladimir; Jørgensen, Jesper Tranekjær; Gustavsson, Tobias; Strømgaard, Kristian; Ingemann Jensen, Andreas T.; Kjær, Andreas; Herth, Matthias M.

In: Nuclear Medicine and Biology, Vol. 132-133, 108905, 2024.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Andersen, IV, Bidesi, NSR, Shalgunov, V, Jørgensen, JT, Gustavsson, T, Strømgaard, K, Ingemann Jensen, AT, Kjær, A & Herth, MM 2024, 'Investigation of imaging the somatostatin receptor by opening the blood-brain barrier with melittin – A feasibility study using positron emission tomography and [64Cu]Cu-DOTATATE', Nuclear Medicine and Biology, vol. 132-133, 108905. https://doi.org/10.1016/j.nucmedbio.2024.108905

APA

Andersen, I. V., Bidesi, N. S. R., Shalgunov, V., Jørgensen, J. T., Gustavsson, T., Strømgaard, K., Ingemann Jensen, A. T., Kjær, A., & Herth, M. M. (2024). Investigation of imaging the somatostatin receptor by opening the blood-brain barrier with melittin – A feasibility study using positron emission tomography and [64Cu]Cu-DOTATATE. Nuclear Medicine and Biology, 132-133, [108905]. https://doi.org/10.1016/j.nucmedbio.2024.108905

Vancouver

Andersen IV, Bidesi NSR, Shalgunov V, Jørgensen JT, Gustavsson T, Strømgaard K et al. Investigation of imaging the somatostatin receptor by opening the blood-brain barrier with melittin – A feasibility study using positron emission tomography and [64Cu]Cu-DOTATATE. Nuclear Medicine and Biology. 2024;132-133. 108905. https://doi.org/10.1016/j.nucmedbio.2024.108905

Author

Andersen, Ida Vang ; Bidesi, Natasha Shalina Rajani ; Shalgunov, Vladimir ; Jørgensen, Jesper Tranekjær ; Gustavsson, Tobias ; Strømgaard, Kristian ; Ingemann Jensen, Andreas T. ; Kjær, Andreas ; Herth, Matthias M. / Investigation of imaging the somatostatin receptor by opening the blood-brain barrier with melittin – A feasibility study using positron emission tomography and [64Cu]Cu-DOTATATE. In: Nuclear Medicine and Biology. 2024 ; Vol. 132-133.

Bibtex

@article{11730782d22f4ab6af0470f0321086c9,
title = "Investigation of imaging the somatostatin receptor by opening the blood-brain barrier with melittin – A feasibility study using positron emission tomography and [64Cu]Cu-DOTATATE",
abstract = "DOTATATE is a somatostatin peptide analog used in the clinic to detect somatostatin receptors which are highly expressed on neuroendocrine tumors. Somatostatin receptors are found naturally in the intestines, pancreas, lungs, and brain (mainly cortex). In vivo measurement of the somatostatin receptors in the cortex has been challenging because available tracers cannot cross the blood-brain barrier (BBB) due to their intrinsic polarity. A peptide called melittin, a main component of honeybee venom, has been shown to disrupt plasma membranes and increase the permeability of biological membranes. In this study, we assessed the feasibility of using melittin to facilitate the passage of [64Cu]Cu-DOTATATE through the BBB and its binding to somatostatin receptors in the cortex. Evaluation included in vitro autoradiography on Long Evans rat brains to estimate the binding affinity of [64Cu]Cu-DOTATATE to the somatostatin receptors in the cortex and an in vivo evaluation of [64Cu]Cu-DOTATATE binding in NMRI mice after injection of melittin. This study found an in vitro Bmax = 89 ± 4 nM and KD = 4.5 ± 0.6 nM in the cortex, resulting in a theoretical binding potential (BP) calculated as Bmax/KD ≈ 20, which is believed suitable for in vivo brain PET imaging. However, the in vivo results showed no significant difference between the control and melittin injected mice, indicating that the honeybee venom failed to open the BBB. Additional experiments, potentially involving faster injection rates are required to verify that melittin can increase brain uptake of non-BBB permeable PET tracers. Furthermore, an evaluation of whether a venom with a narrow therapeutic range can be used for clinical purposes needs to be considered.",
keywords = "Cu, Autoradiography, BBB, Biodistribution, Blood-brain barrier, DOTATATE, Melittin, PET, Somatostatin, SSTR",
author = "Andersen, {Ida Vang} and Bidesi, {Natasha Shalina Rajani} and Vladimir Shalgunov and J{\o}rgensen, {Jesper Tranekj{\ae}r} and Tobias Gustavsson and Kristian Str{\o}mgaard and {Ingemann Jensen}, {Andreas T.} and Andreas Kj{\ae}r and Herth, {Matthias M.}",
note = "Publisher Copyright: {\textcopyright} 2024 The Authors",
year = "2024",
doi = "10.1016/j.nucmedbio.2024.108905",
language = "English",
volume = "132-133",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Investigation of imaging the somatostatin receptor by opening the blood-brain barrier with melittin – A feasibility study using positron emission tomography and [64Cu]Cu-DOTATATE

AU - Andersen, Ida Vang

AU - Bidesi, Natasha Shalina Rajani

AU - Shalgunov, Vladimir

AU - Jørgensen, Jesper Tranekjær

AU - Gustavsson, Tobias

AU - Strømgaard, Kristian

AU - Ingemann Jensen, Andreas T.

AU - Kjær, Andreas

AU - Herth, Matthias M.

N1 - Publisher Copyright: © 2024 The Authors

PY - 2024

Y1 - 2024

N2 - DOTATATE is a somatostatin peptide analog used in the clinic to detect somatostatin receptors which are highly expressed on neuroendocrine tumors. Somatostatin receptors are found naturally in the intestines, pancreas, lungs, and brain (mainly cortex). In vivo measurement of the somatostatin receptors in the cortex has been challenging because available tracers cannot cross the blood-brain barrier (BBB) due to their intrinsic polarity. A peptide called melittin, a main component of honeybee venom, has been shown to disrupt plasma membranes and increase the permeability of biological membranes. In this study, we assessed the feasibility of using melittin to facilitate the passage of [64Cu]Cu-DOTATATE through the BBB and its binding to somatostatin receptors in the cortex. Evaluation included in vitro autoradiography on Long Evans rat brains to estimate the binding affinity of [64Cu]Cu-DOTATATE to the somatostatin receptors in the cortex and an in vivo evaluation of [64Cu]Cu-DOTATATE binding in NMRI mice after injection of melittin. This study found an in vitro Bmax = 89 ± 4 nM and KD = 4.5 ± 0.6 nM in the cortex, resulting in a theoretical binding potential (BP) calculated as Bmax/KD ≈ 20, which is believed suitable for in vivo brain PET imaging. However, the in vivo results showed no significant difference between the control and melittin injected mice, indicating that the honeybee venom failed to open the BBB. Additional experiments, potentially involving faster injection rates are required to verify that melittin can increase brain uptake of non-BBB permeable PET tracers. Furthermore, an evaluation of whether a venom with a narrow therapeutic range can be used for clinical purposes needs to be considered.

AB - DOTATATE is a somatostatin peptide analog used in the clinic to detect somatostatin receptors which are highly expressed on neuroendocrine tumors. Somatostatin receptors are found naturally in the intestines, pancreas, lungs, and brain (mainly cortex). In vivo measurement of the somatostatin receptors in the cortex has been challenging because available tracers cannot cross the blood-brain barrier (BBB) due to their intrinsic polarity. A peptide called melittin, a main component of honeybee venom, has been shown to disrupt plasma membranes and increase the permeability of biological membranes. In this study, we assessed the feasibility of using melittin to facilitate the passage of [64Cu]Cu-DOTATATE through the BBB and its binding to somatostatin receptors in the cortex. Evaluation included in vitro autoradiography on Long Evans rat brains to estimate the binding affinity of [64Cu]Cu-DOTATATE to the somatostatin receptors in the cortex and an in vivo evaluation of [64Cu]Cu-DOTATATE binding in NMRI mice after injection of melittin. This study found an in vitro Bmax = 89 ± 4 nM and KD = 4.5 ± 0.6 nM in the cortex, resulting in a theoretical binding potential (BP) calculated as Bmax/KD ≈ 20, which is believed suitable for in vivo brain PET imaging. However, the in vivo results showed no significant difference between the control and melittin injected mice, indicating that the honeybee venom failed to open the BBB. Additional experiments, potentially involving faster injection rates are required to verify that melittin can increase brain uptake of non-BBB permeable PET tracers. Furthermore, an evaluation of whether a venom with a narrow therapeutic range can be used for clinical purposes needs to be considered.

KW - Cu

KW - Autoradiography

KW - BBB

KW - Biodistribution

KW - Blood-brain barrier

KW - DOTATATE

KW - Melittin

KW - PET

KW - Somatostatin

KW - SSTR

U2 - 10.1016/j.nucmedbio.2024.108905

DO - 10.1016/j.nucmedbio.2024.108905

M3 - Journal article

C2 - 38555651

AN - SCOPUS:85189083148

VL - 132-133

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

M1 - 108905

ER -

ID: 387556481